FDA approved Lipfendra (enlicitide decanoate) on July 15, 2026 to lower LDL cholesterol, per the agency's 2026 novel drug approvals list — the first oral PCSK9 inhibitor to reach the US market, compressing a class built on injections costing thousands per year into a daily pill with the potential for far broader reach.
This article publishes information, not medical advice. Cholesterol medication decisions depend on your cardiovascular risk score, current LDL, and other conditions; review any change with your clinician before switching therapies.
What does a PCSK9 pill do differently?
PCSK9 is a protein the liver uses to clear its own LDL receptors; block it, and the liver recycles more receptors and pulls more LDL from the blood. Injected PCSK9 antibodies (evolocumab, alirocumab) proved the concept and cut LDL by about 60 percent on top of statins, but their list prices — even halved after price wars — kept them in the single-digit percentage of patients who qualify under most formularies. Enlicitide is a small molecule taken orally that binds PCSK9 inside the cell, achieving meaningful LDL reductions at a fraction of the manufacturing cost.
Related stories: FDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs · FDA Approved Icotyde, Taking the Top Psoriasis Target From Injection to Pill.
How big is the unmet need?
Roughly one in three US adults has elevated LDL, and statin intolerance or inadequate response leaves a large middle group between lifestyle change and injectables. Trial data for enlicitide showed LDL reductions in the neighborhood of 50 to 60 percent when added to statin therapy, with the key open question being cardiovascular outcomes — whether lowering LDL this way prevents heart attacks as convincingly as the injectables proved they do.
What should patients ask about coverage?
Expect initial placement on specialty or high tiers with step therapy through statins and ezetimibe. Ask your plan three questions: whether Lipfendra is covered, what documentation of statin intolerance they require, and what your monthly cost lands at after deductible. An oral option only matters if the copay is one you can sustain for years — cholesterol therapy is permanent.
What to watch next
Watch the outcomes-trial readout and whether guidelines add oral PCSK9 inhibition to standard escalation ladders, and watch Part D formularies: a genuinely affordable oral LDL drug would be the first plausible mass-market successor to statins since 1987.
For more context, read FDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs.
For more context, read icotyde fda approval.
For more context, read foundayo fda approval.